Mikart, a clinical and commercial CDMO, today announced that Darrin T. Schellin has joined the company as Chief Executive Officer. In this role, Schellin will lead Mikart's next phase of growth, with ...
The U.S. Lipid Nanoparticle CDMO Market is projected to reach USD 0.44 billion by 2035, while Europe is expected to reach USD 0.27 billion, driven by expanding mRNA, siRNA, gene-editing therapeutics, ...
U.S. market projected to reach USD 13.18 Billion and Europe USD 13.96 Billion by 2035 as cell and gene therapy outsourcing ...
Whether biologic manufacturers decide to outsource or develop products internally, the quality of a CDMO partnership is critical to success, especially for cell and gene therapy products. In the past ...
Bora Pharmaceuticals extended its expansion tear by taking a 30.5% stake in fellow Taiwanese drugmaker Tanvex BioPharma, boosting the CDMO’s biomanufacturing capabilities. The deal, which is expected ...
After pledging earlier this year to bolster its drug substance capabilities in Central Europe, German chemical company Evonik is turning its attention to the U.S. The company is laying out $100 ...
A caffeine giant, a growing CDMO business, and a recovering API segment. Can Aarti Pharmalabs convert a Rs 1,300+ crore capex ...
The evolution of CDMOs has led to increased investment in new technologies, capabilities, and expertise. According to market research, over the next five years the pharma contract development and ...
Indian CDMO stocks are poised for attention as the US House votes on the Biosecure Act, which may limit outsourcing to China.(https://www.emcure.com/) Indian CDMO ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results